Dermatology Department, University of Texas Southwestern Medical Center, Dallas, TX 75390-9069, USA.
Curr Rheumatol Rep. 2013 Feb;15(2):308. doi: 10.1007/s11926-012-0308-9.
There is huge variation in the evaluation, diagnosis, and treatment of patients with morphea (localized scleroderma). In part, this variability results from the lack of validated methods to assess severity and outcomes with a consequent lack of adequate therapeutic trials. Evaluation is also hindered by lack of information regarding the impact of morphea on patients. Recent studies are addressing this gap in knowledge and include: development of clinical outcome measures, validation of imaging studies, publication of consensus treatment plans, and increased understanding of the impact of morphea on patients and parents. The purpose of this review is to summarize the results of these studies and to synthesize the information into a rational approach to the diagnosis and assessment of patients with morphea.
硬斑病（局限性硬皮病）患者的评估、诊断和治疗存在很大差异。部分原因是缺乏评估严重程度和结果的验证方法，因此缺乏足够的治疗试验。由于缺乏有关硬斑病对患者影响的信息，评估也受到阻碍。最近的研究正在解决这一知识空白，包括：开发临床结果测量、验证成像研究、发布共识治疗计划以及增加对硬斑病对患者和父母影响的理解。本综述的目的是总结这些研究的结果，并将信息综合为一种合理的硬斑病患者诊断和评估方法。
